Gefitinib for non-small cell lung cancer patients with liver cirrhosis

Internal Medicine

Volumn 48, Issue 18, 2009, Pages 1677-1679

  Kim, Young Hak ^a   Mio, Tadashi ^a   Mishima, Michiaki ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Gefitinib; Liver cirrhosis

Indexed keywords

GEFITINIB;

ADULT; ARTICLE; BACKACHE; CANCER PATIENT; CANCER STAGING; CASE REPORT; FEMALE; HEADACHE; HUMAN; LIVER CIRRHOSIS; LUNG NON SMALL CELL CANCER; OXYGEN THERAPY; RADIATION DOSE; RADIATION DOSE FRACTIONATION; STEREOTACTIC RADIOSURGERY;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LIVER CIRRHOSIS; LUNG NEOPLASMS; MIDDLE AGED; POINT MUTATION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 70349487335     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.48.2401     Document Type: Article

References (5)

1. Pharmacokinetic data of single dose IRESSA 250 mg in patients with hepatic impairment due to cirrhosis without cancer. In-house data of AstraZeneca (Osaka, Japan), October 2006.
2. Nakagawa K, Tamura T, Negoro S, et al. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors. Ann Oncol 14: 922-930, 2003.
3. FDA. U.S. Food and Drug Administration. MedWatch Safety Alerts for Human MedicalProducts. Retrieved http://www.fda.gov/medwatch/safety/2008/ safety08.htm
4. Mitsudomi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 98: 1817-1824, 2007.
5. Mok T, Wu YL, Thongprasert S, et al. Phase III, randomized, open-label, first-line study of gefitinib vs carboplatin / paclitaxel in clinically selected patients with advanced non-small-cell lung cancer (IPASS). Ann Oncol 19(Sup 8): viii1-viii4, 2008.